The Medical Letter on Drugs and Therapeutics
Durlaza - A 24-Hour Extended-Release Aspirin
The full article is available to subscribers Subscriber Login   

The FDA has approved Durlaza (New Haven Pharmaceuticals), a 24-hour extended-release (ER) aspirin formulation available only by prescription, for secondary prevention of myocardial infarction (MI) and stroke.

RATIONALE — Aspirin's antiplatelet effects are irreversible and persist for the life of the platelet. Immediate-release (IR) aspirin is cleared from serum within 6 hours after a dose. New platelets released into the systemic circulation after IR aspirin is cleared will be active until the next dose is taken. Patients with diabetes and coronary artery disease (CAD) may have high platelet turnover; a study in patients with CAD and type 2 diabetes treated with once-daily low-dose IR aspirin found increased platelet aggregation at the end of the 24-hour dosing interval.1 An ER formulation that releases acetylsalicylic acid (ASA) over a 24-hour period could inhibit ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Durlaza - A 24-Hour Extended-Release Aspirin
Article code: 1486a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian